Building a foundation for the future
- Over £3.3 million invested
Since our founding, the MSA Trust has invested more than £3.3 million in research, funding projects focused on the causes of MSA, potential treatments, biomarkers, and improvements in clinical care. This impact has been made possible entirely through the support of our donors and fundraisers.
- Groundbreaking funded research
We have funded multiple research projects that have advanced scientific understanding of MSA. These include studies exploring DNA changes in brain cells, early biomarkers in blood and spinal fluid, brain energy production, and genetic factors that may increase the risk of developing MSA.
- Three Research Fellows trained
Through our Clinical Research Training Fellowship, delivered in partnership with the Association of British Neurologists, we have supported three exceptional clinician scientists. This programme is helping to develop the next generation of MSA specialists and strengthen expertise within the UK.
- Supporting major clinical trials
The MSA Trust has supported recruitment and awareness for several important clinical trials, including CYPRESS, HORIZON, MASCOT, the Exenatide study and ATH434. This support helps connect people living with MSA to research studies that could shape future treatment options.
- PROSPECT-M-UK and ExPRESS
We are a key funder of PROSPECT‑M‑UK, a major UK‑wide study tracking how MSA progresses over time, which has already led to high‑profile publications in neurology journals. We also support the newer ExPRESS study, which aims to improve earlier diagnosis of MSA across multiple UK sites.
- Annual Research Symposium
Since 2023, we have hosted an annual Research Symposium, bringing together MSA researchers from across the UK and internationally. These events foster collaboration, share emerging findings, and help accelerate progress towards better outcomes for people affected by MSA.